VALANX and FinaBio partner for rapid conjugate vaccine development
Key Highlights: VALANX Biotech and FinaBio sign joint licensing agreement to commercialise ready-to-conjugate vaccine carrier protein CRM197 will enable rapid development of conjugate vaccines. The new product enables the rapid, high-efficiency conjugation of carrier proteins to polysaccharide antigens for the generation of conjugate vaccines. Under the commercialisation agreement, VALANX will produce ClickCRM using its
READ MORE